| 3.64 -0.08 (-2.15%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.85 | 1-year : | 5.69 |
| Resists | First : | 4.15 | Second : | 4.88 |
| Pivot price | 3.98 |
|||
| Supports | First : | 2.99 | Second : | 2.49 |
| MAs | MA(5) : | 3.7 |
MA(20) : | 4 |
| MA(100) : | 7.51 |
MA(250) : | 0 | |
| MACD | MACD : | -0.5  |
Signal : | -0.6 |
| %K %D | K(14,3) : | 8.2 |
D(3) : | 9.2 |
| RSI | RSI(14): 33.2 |
|||
| 52-week | High : | 14.25 | Low : | 2.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AVXL ] has closed above bottom band by 15.3%. Bollinger Bands are 58.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.71 - 3.74 | 3.74 - 3.76 |
| Low: | 3.51 - 3.54 | 3.54 - 3.56 |
| Close: | 3.6 - 3.65 | 3.65 - 3.68 |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Wed, 24 Dec 2025
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Mon, 22 Dec 2025
Anavex Life Sciences' (AVXL) Buy Rating Reiterated at HC Wainwright - MarketBeat
Fri, 19 Dec 2025
D. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy Recommendation - Nasdaq
Thu, 18 Dec 2025
EU regulators asked to revisit an experimental pill for early Alzheimer’s - Stock Titan
Tue, 02 Dec 2025
Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's - Seeking Alpha
Tue, 02 Dec 2025
Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 89 (M) |
| Shares Float | 86 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 37 (%) |
| Shares Short | 25,140 (K) |
| Shares Short P.Month | 26,660 (K) |
| EPS | -0.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.6 % |
| Return on Equity (ttm) | -43.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -6.75 |
| PEG Ratio | 0 |
| Price to Book value | 3.3 |
| Price to Sales | 0 |
| Price to Cash Flow | -8.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|